

## **Package leaflet: Information for the patient**

### **Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab**

**Read all of this leaflet carefully before you start using this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
- Your doctor will also give you a Patient Alert Card for you to keep with you at all times.

#### **What is in this leaflet**

1. What Entyvio is and what it is used for
2. What you need to know before you are given Entyvio
3. How Entyvio will be given
4. Possible side effects
5. How to store Entyvio
6. Contents of the pack and other information

#### **1. What Entyvio is and what it is used for**

Entyvio contains the active substance vedolizumab. Vedolizumab belongs to a group of biological medicines called monoclonal antibodies (MAbs). Vedolizumab blocks a protein on the surface of white blood cells that cause the inflammation in ulcerative colitis and Crohn's disease, and so the amount of inflammation is reduced.

Entyvio is used to treat the signs and symptoms in adults of:

- moderately to severely active ulcerative colitis
- moderately to severely active Crohn's disease.

#### **Ulcerative colitis**

Ulcerative colitis is an inflammatory disease of the large bowel. If you have ulcerative colitis, you will first be given other medicines. If you do not respond well enough or are intolerant to these medicines, your doctor may give you Entyvio to reduce the signs and symptoms of your disease.

#### **Crohn's disease**

Crohn's disease is an inflammatory disease of the gastrointestinal tract. If you have Crohn's disease you will first be given other medicines. If you do not respond well enough or are intolerant to these medicines, your doctor may give you Entyvio to reduce the signs and symptoms of your disease.

#### **2. What you need to know before you are given Entyvio**

##### **You must not be given Entyvio:**

- if you are allergic to vedolizumab or any of the other ingredients of this medicine (listed in section 6).
- if you have an active severe infection, for example, tuberculosis, blood poisoning, severe gastroenteritis, nervous system infection.

#### **Warnings and precautions**

Talk to your doctor or nurse before being given Entyvio.

**Tell your doctor or nurse immediately** when you first receive this medicine, during treatment, and between doses:

- if you experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. These may all be symptoms of a **serious and potentially fatal brain condition** known as progressive multifocal leukoencephalopathy (PML).
- if you have an **infection**, or think you have an infection, if you develop chills, shivering, persistent cough or a high fever. Some infections may become serious and possibly even life-threatening if left untreated.
- if you experience signs of **an allergic reaction or other reaction to the infusion** such as wheezing, difficulty breathing, hives, itching, swelling or dizziness. These could occur during or after the infusion. For more detailed information, see infusion and allergic reactions in section 4.
- if you are going to receive any **vaccination** or have recently had a vaccination. Entyvio may affect the way you respond to a vaccination.
- if you have cancer, tell your doctor. Your doctor will have to decide if you can still be given Entyvio.
- if you are not feeling any better as vedolizumab may take up to 14 weeks to work in some patients with very active Crohn's disease.

### **Children and adolescents**

Entyvio is not recommended for use in children or adolescents (under 18 years of age) due to the lack of information regarding the use of this medicine in this age group.

### **Other medicines and Entyvio**

Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.

Entyvio should not be given with other biologic medicines that suppress your immune system as the effect of this is not known.

If you have previously taken natalizumab (a medicine used to treat multiple sclerosis) or rituximab (a medicine used to treat certain types of cancer and rheumatoid arthritis), tell your doctor, who will decide if you can be given Entyvio.

### **Pregnancy and breast-feeding**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

The effects of Entyvio in pregnant women are not known. Therefore, this medicine is not recommended for use during pregnancy unless you and your doctor decide that the benefit to you clearly outweighs the potential risk to yourself and your baby.

If you are a woman of childbearing potential, you are advised to avoid becoming pregnant while using Entyvio. You should use adequate contraception during treatment and for at least 4.5 months after the last treatment.

Tell your doctor if you are breast-feeding or planning to breast-feed. It is not known whether Entyvio passes into breast milk and if so what effect this may have on your baby.

### **Driving and using machines**

This medicine has a minor influence on your ability to drive or use tools or machines. A small number of patients have felt dizzy after receiving Entyvio. If you feel dizzy, do not drive or use tools or machines.

### **3. How Entyvio will be given**

#### **Dose and frequency**

Treatment with Entyvio is the same for ulcerative colitis and Crohn's disease.

The recommended dose is 300 mg of Entyvio given as follows (see table below):

Treatment (infusion) number	Timing of treatment (infusion)
Treatment 1	0 weeks
Treatment 2	2 weeks after Treatment 1
Treatment 3	6 weeks after Treatment 1
Further treatments	Every 8 weeks

Your doctor may decide to alter this treatment schedule depending on how well Entyvio works for you.

- The infusion will be given to you, by your doctor or nurse, through a drip in one of the veins in your arm (intravenous infusion) over about 30 minutes.
- For your first 2 infusions, your doctor or nurse will monitor you closely during the infusion and for approximately 2 hours after you have completed the infusion. For all subsequent infusions (after the first two), you will be monitored during the infusion and for approximately 1 hour after you have completed the infusion.

#### **If you forget or miss your Entyvio infusion**

If you forget or miss an appointment to receive the infusion, make another appointment as soon as possible.

#### **If you stop using Entyvio**

You should not stop using Entyvio without talking with your doctor first.

If you have any further questions on the use of this medicine, ask your doctor or nurse.

### **4. Possible side effects**

Like all medicines, this medicine can cause side effects although not everybody gets them.

Possible serious side effects include infusion reactions or allergic reactions (may affect up to 1 in 100 people) and infections (may affect up to 1 in 10 people).

Tell your doctor **immediately** if you notice any of the following:

- wheezing or difficulty breathing
- hives
- itching of the skin
- swelling
- feeling sick
- pain at the infusion site
- redness of skin
- chills or shivering
- high fever or rash

Other side effects that you may experience while taking Entyvio are listed below. Tell your doctor **as soon as possible** if you notice any of the following:

**Very common side effects (may affect more than 1 in 10 people):**

- common cold
- joint pain
- headache

**Common side effects (may affect up to 1 in 10 people):**

- fever
- chest infection
- tiredness
- cough
- flu (influenza)
- back pain
- throat pain
- sinus infection
- itching / itchiness
- rash and redness
- pain in the limb
- muscle cramps
- muscle weakness
- throat infection
- stomach flu
- anal infection
- anal sore
- hard faeces
- bloated stomach
- passing gas
- high blood pressure
- prickling or tingling
- heart burn
- haemorrhoids
- blocked nose
- eczema
- night sweats
- acne (pimples)

**Uncommon side effects (may affect up to 1 in 100 people)**

- redness and tenderness of hair follicle
- throat and mouth yeast infection
- vaginal infection

**Very rare side effects (may affect up to 1 in 10,000 people)**

- pneumonia
- blurred vision (loss of sharpness of eyesight)
- sudden, severe allergic reaction which can cause breathing difficulty, swelling, fast heartbeat, sweating, drop in blood pressure, light-headedness, loss of consciousness and collapse (anaphylactic reaction and anaphylactic shock)

**Reporting of side effects**

If you get any side effects talk to your doctor. This includes any side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website:

[www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

## 5. How to store Entyvio

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after “EXP”. The expiry date refers to the last day of that month.

Entyvio is given by a doctor or nurse and patients should not need to store or handle Entyvio.

Entyvio is for single-use only.

**Unopened vial:** Store in a refrigerator (2 °C-8 °C). Keep the vial in the original carton in order to protect from light.

**Reconstituted and diluted solutions:** Use immediately. If this is not possible, reconstituted solution in the vial can be stored for up to 8 hours at 2 °C-8 °C. Diluted solution in sodium chloride 9 mg/mL (0.9%) solution for injection can be stored up to 12 hours at a room temperature of not above 25 °C, or up to 24 hours in a refrigerator (2 °C-8 °C), or for up to 12 hours at room temperature and in a refrigerator (2 °C-8 °C), up to a combined total of 24 hours. A 24 hour period may include up to 8 hours at 2 °C-8 °C for reconstituted solution in the vial and up to 12 hours at 20 °C-25 °C for diluted solution in the infusion bag but the infusion bag must be stored in the refrigerator (2 °C-8 °C) for the rest of the 24 hour period. Any time that the reconstituted solution was held in the vial should be subtracted from the time the solution may be held in the infusion bag.

Do not freeze.

Do not use this medicine if you notice any particles in the liquid or discolouration prior to administration.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

## 6. Contents of the pack and other information

### What Entyvio contains

The **active substance** is vedolizumab. Each vial contains 300 mg of vedolizumab.

The **other ingredients** are L-histidine, L-histidine monohydrochloride, L-arginine hydrochloride, sucrose, and polysorbate 80.

### What Entyvio looks like and contents of the pack

Entyvio is a white to off-white powder for concentrate for solution for infusion provided in a glass vial with a rubber stopper and a plastic cap.

Each pack of Entyvio consists of one vial.

### Marketing Authorisation Holder

Takeda Pharma A/S  
Dybendal Alle 10  
2630 Taastrup  
Denmark

**Manufacturer**

Delpharm Novara S.r.l.  
Via Crosa, 86  
28065 Cerano (NO)  
Italy

Takeda Austria GmbH  
St. Peter-Straße 25  
4020 Linz  
Austria

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**

Takeda Belgium  
Tel./Tél.: +32 2 464 06 11  
[takeda-belgium@takeda.com](mailto:takeda-belgium@takeda.com)

**България**

Такеда България  
Тел.: +359 2 958 27 36

**Česká republika**

Takeda Pharmaceuticals Czech Republic s.r.o.  
Tel: +420 731 620 870

**Danmark**

Takeda Pharma A/S  
Tlf./Tel.: +45 46 77 11 11

**Deutschland**

Takeda GmbH  
Tel.: +49 (0) 800 825 3325  
[medinfo@takeda.de](mailto:medinfo@takeda.de)

**Eesti**

Takeda Pharma AS  
Tel.: +372 6177 669  
[info@takeda.ee](mailto:info@takeda.ee)

**Ελλάδα**

TAKEDA ΕΛΛΑΣ Α.Ε.  
Τηλ.: +30 210 6387800  
[gr.info@takeda.com](mailto:gr.info@takeda.com)

**España**

Takeda Farmacéutica España S.A.  
Tel.: +34 917 14 99 00  
[spain@takeda.com](mailto:spain@takeda.com)

**France**

Takeda France  
Tel.: +33 1 46 25 16 16

**Lietuva**

Takeda, UAB  
Tel.: +370 521 09 070  
[lt-info@takeda.com](mailto:lt-info@takeda.com)

**Luxembourg/Luxemburg**

Takeda Belgium  
Tel/Tél: +32 2 464 06 11  
[takeda-belgium@takeda.com](mailto:takeda-belgium@takeda.com)

**Magyarország**

Takeda Pharma Kft.  
Tel.: +361 2707030  
[info-hu@takeda.com](mailto:info-hu@takeda.com)

**Malta**

Takeda Italia S.p.A.  
Tel.: +39 06 502601

**Nederland**

Takeda Nederland bv  
Tel.: +31 23 56 68 777  
[nl.medical.info@takeda.com](mailto:nl.medical.info@takeda.com)

**Norge**

Takeda AS  
Tlf.: +47 6676 3030  
[infonorge@takeda.com](mailto:infonorge@takeda.com)

**Österreich**

Takeda Pharma Ges.m.b.H.  
Tel.: +43 (0) 800 20 80 50

**Polska**

Takeda Polska Sp. z o.o.  
Tel.: +48 22 608 13 00

**Portugal**

Takeda Farmacêuticos Portugal, Lda.  
Tel.: +351 21 120 1457

**Hrvatska**

Takeda Pharmaceuticals Croatia d.o.o.  
Tel: +385 1 377 88 96

**Ireland**

Takeda Products Ireland Ltd.  
Tel.: +353 (0) 1 6420021

**Ísland**

Vistor hf.  
Tel.: +354 535 7000  
[vistor@vistor.is](mailto:vistor@vistor.is)

**Italia**

Takeda Italia S.p.A  
Tel.: +39 06 502601

**Κύπρος**

A.Potamitis Medicare Ltd  
Τηλ: +357 22583333  
[info@potamitismedicare.com](mailto:info@potamitismedicare.com)

**Latvija**

Takeda Latvia SIA  
Tel.: +371 67840082

**România**

Takeda Pharmaceuticals SRL  
Tel.: +40 21 335 03 91

**Slovenija**

Takeda GmbH, Podružnica Slovenija  
Tel.: +386 (0) 59 082 480

**Slovenská republika**

Takeda Pharmaceuticals Slovakia s.r.o.  
Tel.: +421 (2) 20 602 600

**Suomi/Finland**

Takeda Oy  
Puh./Tel.: +358 20 746 5000  
[infoposti@takeda.com](mailto:infoposti@takeda.com)

**Sverige**

Takeda Pharma AB  
Tel.: +46 8 731 28 00  
[infosweden@takeda.com](mailto:infosweden@takeda.com)

**United Kingdom**

Takeda UK Ltd  
Tel.: +44 (0)1628 537 900

**This leaflet was last revised in December 2018.**

**Other sources of information**

This leaflet is available in formats suitable for the blind or partially sighted patient and can be requested from respective local representative of the Marketing Authorisation Holder.

Detailed information on this medicine is available on the European Medicines Agency web site:  
<http://www.ema.europa.eu>.

---

The following information is intended for healthcare professionals only:

### Instructions for reconstitution and infusion

1. Use aseptic technique when preparing Entyvio solution for intravenous infusion.
2. Remove flip-off cap from the vial and wipe with alcohol swab. Reconstitute vedolizumab with 4.8 mL of sterile water for injections at room temperature (20 °C-25 °C), using a syringe with a 21-25 gauge needle.
3. Insert needle into the vial through the centre of the stopper and direct the stream of liquid to the wall of the vial to avoid excessive foaming.
4. Gently swirl the vial for at least 15 seconds. Do not vigorously shake or invert.
5. Let the vial sit for up to 20 minutes at room temperature (20 °C-25 °C), to allow for reconstitution and for any foam to settle; the vial can be swirled and inspected for dissolution during this time. If not fully dissolved after 20 minutes, allow another 10 minutes for dissolution.
6. Inspect the reconstituted solution visually for particulate matter and discoloration prior to dilution. Solution should be clear or opalescent, colourless to light yellow and free of visible particulates. Reconstituted solution with uncharacteristic colour or containing particulates must not be administered.
7. Once dissolved, gently invert vial 3 times.
8. Immediately withdraw 5 mL (300 mg) of reconstituted Entyvio using a syringe with a 21-25 gauge needle.
9. Add the 5 mL (300 mg) of reconstituted Entyvio to 250 mL of sterile sodium chloride 9 mg/mL (0.9%) solution for injection, and gently mix the infusion bag (5 mL of sodium chloride 9 mg/mL (0.9%) solution for injection does not have to be withdrawn from the infusion bag prior to adding Entyvio). Do not add other medicinal products to the prepared infusion solution or intravenous infusion set. Administer the infusion solution over 30 minutes.

Once reconstituted, the infusion solution should be used as soon as possible.

	<b>Storage Condition</b>	
	Refrigerator (2 °C-8 °C)	20 °C-25 °C
Reconstituted solution in the vial	8 hours	Do not hold <sup>1</sup>
Diluted solution in sodium chloride 9 mg/mL (0.9%) solution for injection	24 hours <sup>2, 3</sup>	12 hours <sup>2</sup>

<sup>1</sup> Up to 30 minutes are allowed for reconstitution

<sup>2</sup> This time assumes the reconstituted solution is immediately diluted in the sodium chloride 9 mg/mL (0.9%) solution for injection and held in the infusion bag only. Any time that the reconstituted solution was held in the vial should be subtracted from the time the solution may be held in the infusion bag.

<sup>3</sup> This period may include up to 12 hours at 20 °C-25 °C.

Do not freeze. Do not store any unused portion of the reconstituted solution or infusion solution for reuse.

Each vial is for single-use only.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.